Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals stock opened at $0.58 on Tuesday. The company has a 50 day moving average price of $0.77 and a 200 day moving average price of $0.89. Citius Pharmaceuticals has a 52 week low of $0.48 and a 52 week high of $2.48. The firm has a market capitalization of $15.92 million, a price-…

LYMPHIR net sales hit $1,667,298 this quarter while net loss reached $26,609,695. Filing highlights going concern risk, a $19,733,307 CMO contract charge, and a new $25.0 million secured loan.

Citius Pharmaceuticals, Inc. reported third-quarter fiscal 2026 results, recording revenue of $1.67M for the three months ended March 31, 2026, and a net loss applicable to common stockholders of $(21.23M). Diluted loss per share was $(0.95) for the quarter.Financial HighlightsBusiness ...

Citius Pharmaceuticals booked $5.6M LYMPHIR revenue but lost $37.5M, burned $14.3M operating cash, recorded large CMO termination charges and warned of going concern risk beyond November 2026 despite new equity and loan financings.

Citius Pharmaceuticals reported fiscal second quarter results for the period ended March 31, 2026, driven by the commercial launch of LYMPHIR. The company recorded $1.7 million in product revenue for the quarter and $5.6 million for the six months ended March 31, 2026, while reporting a net ...